Do Youn Oh
About
Do Youn Oh is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, Do Youn Oh has authored 20 papers receiving a total of 409 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in Do Youn Oh's work include Lung Cancer Treatments and Mutations (6 papers), Cancer Treatment and Pharmacology (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). Do Youn Oh is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Cancer Treatment and Pharmacology (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). Do Youn Oh collaborates with scholars based in South Korea, United States and Taiwan. Do Youn Oh's co-authors include Seock‐Ah Im, Sae‐Won Han, Yung‐Jue Bang, Young‐Kwang Yoon, Tae‐You Kim, Tae‐You Kim, Hwang‐Phill Kim, Hyung-Seok Hur, Kyung Hae Jung and Tae Won Kim and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Cancer Letters.
In The Last Decade
Do Youn Oh
18 papers receiving 403 citations
Peers
Do Youn Oh
Tomohiro Nogami Japan
Carolina Ortiz Spain
Luca Livraghi Italy
Séverine Sarp Switzerland
Syed A. Ahmed United States
T. Gulliford United Kingdom
Davide Caruso Italy
Marion L. Hartley United States
Ali Saber Netherlands
Christina L. Gersch United States
Citations per year, relative to Do Youn Oh Do Youn Oh (= 1×)
peers
Tomohiro Nogami
Countries citing papers authored by Do Youn Oh
Since
Specialization
Citations
This map shows the geographic impact of Do Youn Oh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Do Youn Oh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Do Youn Oh more than expected).
Fields of papers citing papers by Do Youn Oh
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Do Youn Oh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Do Youn Oh. The network helps show where Do Youn Oh may publish in the future.
Co-authorship network of co-authors of Do Youn Oh
This figure shows the co-authorship network connecting the top 25 collaborators of Do Youn Oh. A scholar is included among the top collaborators of Do Youn Oh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Do Youn Oh. Do Youn Oh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Garralda, Elena, Do Youn Oh, Antoîne Italiano, et al.. (2023). Pharmacokinetics (PK) of Tiragolumab in First‐in‐Human Study in Patients with Mixed Solid Tumors (GO30103). The Journal of Clinical Pharmacology. 64(5). 544–554.
2.
Kim, Kyubo, et al.. (2019). Chemoradiotherapy after gemcitabine plus erlotinib in patients with locally advanced pancreatic cancer.. PubMed. 22(4). 1046–1052.
3.
Ueno, Makoto, Masafumi Ikeda, Hiroshi Ishii, et al.. (2017). A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo. Cancer Chemotherapy and Pharmacology. 80(2). 307–315.
4.
Lim, Yoojoo, Kyung-Hun Lee, Bhumsuk Keam, et al.. (2017). Korean Cancer Patients’ Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate. Cancer Research and Treatment. 49(4). 1033–1043.
5.
Jin, Meihua, et al.. (2017). Abstract 5869: Resistance mechanism against trastuzumab in HER2-positive cancer cells and its negation by Src inhibition. Cancer Research. 77(13_Supplement). 5869–5869.
6.
Park, Jin Hyun, Seock‐Ah Im, Ja Min Byun, et al.. (2017). Cyclophosphamide, Methotrexate, and 5-Fluorouracil as Palliative Treatment for Heavily Pretreated Patients with Metastatic Breast Cancer: A Multicenter Retrospective Analysis. Journal of Breast Cancer. 20(4). 347–347.
7.
Park, Hae Jin, Kyubo Kim, Eui Kyu Chie, et al.. (2014). Chemoradiotherapy for extrahepatic bile duct cancer with gross residual disease after surgery.. PubMed. 34(11). 6685–90.
8.
Yeo, Winnie, Kyung Hae Jung, Seock‐Ah Im, et al.. (2013). Phase III, Multicenter, Randomized Trial of Maintenance Chemotherapy Versus Observation in Patients With Metastatic Breast Cancer After Achieving Disease Control With Six Cycles of Gemcitabine Plus Paclitaxel As First-Line Chemotherapy: KCSG-BR07-02. Journal of Clinical Oncology. 31(14). 1732–1739.
9.
Yeo, Winnie, Kyung Hae Jung, Seock‐Ah Im, et al.. (2013). PR99 QUALITY OF LIFE (QOL) IN METASTATIC BREAST CANCER PATIENTS WITH MAINTENANCE PACLITAXEL PLUS GEMCITABINE (PG) CHEMOTHERAPY: RESULTS FROM PHASE III, MULTICENTER, RANDOMIZED TRIAL OF MAINTENANCE CHEMOTHERAPY VERSUS OBSERVATION (KCSG-BR07-02). The Breast. 22. S53–S53.
10.
Yoon, Young‐Kwang, Seock‐Ah Im, Ahrum Min, et al.. (2012). Sunitinib synergizes the antitumor effect of cisplatin via modulation of ERCC1 expression in models of gastric cancer. Cancer Letters. 321(2). 128–136.
11.
Im, Young‐Hyuck, Winnie Yeo, Kyung Hae Jung, et al.. (2012). A phase III, multicenter, randomized trial of maintenance versus observation after achieving clinical response in patients with metastatic breast cancer who received six cycles of gemcitabine plus paclitaxel as first-line chemotherapy (KCSG-BR 0702, NCT00561119).. Journal of Clinical Oncology. 30(15_suppl). 1003–1003.
12.
Yoon, Young‐Kwang, Hwang‐Phill Kim, Sang‐Hyun Song, et al.. (2011). Down-regulation of mitogen-inducible gene 6, a negative regulator of EGFR, enhances resistance to MEK inhibition in KRAS mutant cancer cells. Cancer Letters. 316(1). 77–84.
13.
Kim, Kyubo, Eui Kyu Chie, Wonshik Han, et al.. (2011). Concurrent versus sequential administration of CMF chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer.. PubMed. 97(3). 280–5.
14.
Kim, Ji Won, Ji Hyun Kwon, Do Youn Oh, et al.. (2010). A case of primary breast synovial sarcoma diagnosed in a young female patient. The Korean Journal of Internal Medicine. 78(5). 640–644.
15.
Yoon, Young‐Kwang, Sae‐Won Han, Do Youn Oh, et al.. (2010). KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach. Molecular Carcinogenesis. 49(4). 353–362.
16.
Kim, Jee Hyun, Keun‐Wook Lee, Yeul Hong Kim, et al.. (2010). Individualized Tumor Response Testing for Prediction of Response to Paclitaxel and Cisplatin Chemotherapy in Patients with Advanced Gastric Cancer. Journal of Korean Medical Science. 25(5). 684–684.
17.
Yoon, Young‐Kwang, Hwang‐Phill Kim, Sae‐Won Han, et al.. (2009). Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. Molecular Cancer Therapeutics. 8(9). 2526–2536.
18.
Lee, Jeeyun, Kyung Hae Jung, Young Suk Park, et al.. (2009). Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study. Cancer Chemotherapy and Pharmacology. 64(4). 657–663.
19.
Oh, Do Youn, Jee Hyun Kim, Se‐Hoon Lee, et al.. (2006). Artificial nutrition and hydration in terminal cancer patients: the real and the ideal. Supportive Care in Cancer. 15(6). 631–636.
20.
Oh, Do Youn, Do Yeun Kim, Jee Hyun Kim, et al.. (2001). Efficacy of Low-dose Paclitaxel and Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer. Cancer Research and Treatment. 33(6). 469–473.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Tomohiro Nogami Breakdown of academic impact, for papers by Carolina Ortiz Breakdown of academic impact, for papers by Luca Livraghi Breakdown of academic impact, for papers by Séverine Sarp Breakdown of academic impact, for papers by Syed A. Ahmed Breakdown of academic impact, for papers by T. Gulliford Breakdown of academic impact, for papers by Davide Caruso Breakdown of academic impact, for papers by Marion L. Hartley Breakdown of academic impact, for papers by Ali Saber Breakdown of academic impact, for papers by Christina L. Gersch